POSSibilities

Pfizer Oncology Scientific Symposium

10 October 2017. Venue: Stockholm TBD

To: Head of Department
Cc: Oncologist and Pulmonologist
with interest in Renal Cell Carcinoma,
Non-Small Cell Lung Cancer or
Metastatic Breast Cancer





Welcome to a highly scientific event

This educational day will highlight and discuss the latest thinking around standard of care treatment regimens across therapeutic classes in Renal Cell Carcinoma, Non-Small Cell Lung Cancer or Metastatic Breast Cancer.

Renal Cell Carcinoma: Standard treatments in first-line and second-line metastatic RCC; how to optimize therapy management and the choice of targeted and IO agents throughout the treatment continuum.

Main speaker: Dr. Eric Jonasch, MD Anderson Cancer Center. Houston. USA

Non-Small Cell Lung Cancer: Treatment sequencing approaches and testing algorithms for previously untreated and recurrent ALK-, EGFR-, ROS1- and PD-L1-positive NSCLC. Main speaker: Dr. Federico Cappuzzo, Onco-Hematology Department, AUSL Romagna, Ravenna, Italy.

Metastatic Breast Cancer: Current treatment options and evolving role of CDK inhibition in combination with endocrine therapy for first- and second-line HR+/HER2- mBC.

Main speaker: Dr. Elizabeth Comen, Memorial Sloan-Kettering Cancer Center, New York, USA.

Best regards,
Dr. Thomas Wahlgren
Senior Medical Advisor Oncology, Pfizer Sweden
+46 768 892 947
thomas.wahlgren@pfizer.com



Adresskälla. Försändelsen är utsänd med stöd av uppgifter ur Hälso-& Sjukvårdens Adressregister (HSAR), av Pfizer, som är anslutet till integritetsskyddsprogram för HSAR. Ytterligare information erhålls av IMS Health Technology Solutions Sweden, 08-555 214 20 eller www.hsar.se.

AGENDA 10.00-16.30

Coffee and registration
Welcome and international speakers
Lunch
Therapy specific workhops moderated by Pfizer medical and international speakers
Coffee

Closing remarks

